Deborah V. Ascheim
- ASSOCIATE PROFESSOR Health Evidence and Policy
- ASSOCIATE PROFESSOR Medicine, Cardiology
- General Cardiology
MD, New York University School of Medicine
Residency, General Medicine
New York Presbyterian - Weill Cornell Medical Center
New York Presbyterian - Weill Cornell Medical Center
Dr. Davis Ascheim is a cardiologist with expertise in congestive heart failure and extensive experience in clinical investigation in the cardiovascular domain, encompassing both trial design and conduct, She currently serves as Director of the Clinical Coordinating Core (CCC), for the Cardiothoracic Surgical Trials Network Data Coordinating Center (DCC). Her particular expertise is in clinical evaluation of surgical and device interventions, and also currently serves as the DCC PI for the NHLBI funded Hybrid Revascularization Observational Study. She currently serves on the Leadership Team for the CTSN DCC, in which capacity she provides cardiology oversight for the DCC and Network activities, interacts with the cardiologists at the sites, assist in the design of Network protocols and data collection tools, liaison with site PIs regarding patient enrollment, interacts with the CTSN Core Labs’ leadership on trial and clinical issues, and provides clinical expertise for the design of current and new CTSN trials. She has significant experience in the clinical evaluation of both cell and gene therapies for cardiovascular applications, and currently serves as the (Multiple) PI of a CTRIP grant, Targeted Gene Therapy for the Treatment of Heart Failure. This experience has been useful for the development of the CTSN regenerative medicine research agenda, in particular the development and current conduct of the CTSN LVAD Cell Therapy trial. She has served in the past as the site Principal Investigator for numerous heart failure clinical trials, as well as on numerous leadership and advisory committees for heart failure and cardiac device trials.
Smith P, Michler R, Woo J, Alexander J, Puskas J, D’Allesandro D, Hahn R, Williams J, Matthews J, Dent J, Ferguson B, Moquete E, Page M, Jeffries N, O’Gara P, Ascheim DD. Design, Rationale, and Initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: A Report from the Cardiothoracic Surgical Trials Network. J Thor Cardiovasc Surgery. 2012 Jan; 143(1): 111-7, 117.e1. Epub 2011 Jul 23 .
Iribarne A, Gelijns AC, Acker MA, Ascheim DD. Innovative Clinical Trial Design in Cardiac Surgery. Seminars in Thoracic and Cardiovascular Surgery. 2011; 23(4): 271-273.
Gillinov AM, Argenziano M, Blackstone EH, Iribarne A, DeRose JJ, Ailawadi G, Russo MJ, Ascheim DD, Parides MK, Rodriguez E, Bouchard D, Taddei-Peters WC, Geller NL, Acker MA, Gelijns AC. Designing comparative effectiveness trials of surgical ablation for atrial fibrillation: Experience of the Cardiothoracic Surgical Trials Network. J Thorac Cardiovasc Surg. 2011 Aug; 142(2): 257-264.e2.Epub 2011 May 25.
Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, Gelijns AC, Hong KN, Teuteberg JJ. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. 2010 Dec 18;(Epub ahead of print).
Russo MJ, Iribarne A, Easterwood R, Ibrahimiye AN, Davies R, Hong KN, Ascheim DD, Gelijns AC, Naka Y. Post-heart transplant survival is inferior at low-volume centers across all risk strata. Circulation. 2010 Sep 14; 122(11 Suppl): S85-91.
Holman WL, Kirklin JK, Naftel DC, Kormos RL, Desvigne-Nickens P, Camacho M, Ascheim DD. Early Infection after Implantation of Mechanical Circulatory Support Devices. J Thorac Cardiovasc Surg. 2010 Jun; 139(6): 1632-1636.
Russo MJ, Hong KN, Davies RR, Chen JM, Sorabella RA, Ascheim DD, Williams MR, Gelijns AC, Stewart AS, Argenziano M, Naka Y. Post-transplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices. J Thorac Cardiovasc Surg. 2009 Dec; 138(6): 1425-32.e1-3.
Gelijns AC, Ascheim DD, Parides MK, Kent KC, Moskowitz AJ. Randomized trials in surgery. Surgery. 2009 Jun; 145(6): 581-7.
Iribarne A, Russo MJ, Moskowitz AJ, Ascheim DD, Brown LD, Gelijns AC. Assessing technological change in cardiothoracic surgery. Semin Thorac Cardiovasc Surg. 2009 Spring; 21(1): 28-34.
Ascheim DD, Gelijns AC, Rose EA. Innovation with experience using implantable Left Ventricular Assist Devices. Circulation: Heart Failure. 2009 January; 2(1): 1-2.
Russo MJ, Gelijns A, Stevenson LW, Sampat B, Aaronson KD, Renlund DG, Ascheim DD, Hong KN, Oz MC, Moskowitz AJ, Rose EA, Miller L. The cost of medical management in advanced heart failure during the final two years of life. For the Rematch Investigators. J Cardiac Failure. 2008 Oct; 14 (8): 651-658.
Parides M, Moskowitz AJ, Ascheim DD, Rose EA, Gelijns AC. Progress versus Precision: Challenges in Clinical Trial Design for Left Ventricular Assist Devices. Ann Thorac Surg. 2006 Sep; 82(3): 1140-6.
Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). REMATCH Investigators. Circulation. 2004 Aug 24; 110(8): 975-81. Epub 2004 Aug 16.
Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001 Nov 15; 345(20): 1435-43.
Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, Heitjan DF, Meier P, Ascheim DD, et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg. 1999 Mar; 67(3): 723-30.
- The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Bridge to Transplant Patients
- Surgical Interventions for Moderate Ischemic Mitral Regurgitation
- LVAD Therapy: Exploring the Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Ascheim during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- BackBeat Medical
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 2nd Floor Room 53
1425 Madison Avenue
New York, NY 10029